# Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours

> **NCT03697304** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 211 (actual)

## Conditions studied

- Neoplasm Metastasis
- Advanced Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** Ezabenlimab
- **DRUG:** BI 754111
- **DRUG:** BI 836880

## Key facts

- **NCT ID:** NCT03697304
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-19
- **Primary completion:** 2024-12-03
- **Final completion:** 2024-12-03
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697304, "Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03697304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*